

## Original Article

# Economic valuation of the mortality benefits of a regulation on SO<sub>2</sub> in 20 European cities

Olivier Chanel<sup>1</sup>, Susann Henschel<sup>2</sup>, Patrick G. Goodman<sup>2</sup>, Antonis Analitis<sup>3</sup>, Richard W. Atkinson<sup>4</sup>, Alain Le Tertre<sup>5</sup>, Ariana Zeka<sup>6</sup> and Sylvia Medina<sup>5</sup> on behalf of the Aphekom group

1 Aix-Marseille School of Economics, Aix-Marseille University, CNRS & EHESS, GREQAM et IDEP, Marseilles, France

2 School of Physics, Dublin Institute of Technology, Dublin, Ireland

3 Department of Hygiene, Epidemiology and Medical Statistics, Medical School, University of Athens, Athens, Greece

4 St. George's, University of London, London, UK

5 French Institute for Public Health Surveillance, InVS, Saint-Maurice, France

6 Institute for the environment, Brunel University, London, UK

**Correspondence:** Olivier Chanel, Aix-Marseille School of Economics, Aix-Marseille University, GREQAM, 2 rue de la Charité, 13236 Marseille cedex 02, France, Tel: +33 (0)4 91 14 07 80, Fax: +33 (0)4 91 90 02 27, e-mail: olivier.chanel@univ-amu.fr

**Background:** Since the 1970s, legislation has led to progress in tackling several air pollutants. We quantify the annual monetary benefits resulting from reductions in mortality from the year 2000 onwards following the implementation of three European Commission regulations to reduce the sulphur content in liquid fuels for vehicles.

**Methods:** We first compute premature deaths attributable to these implementations for 20 European cities in the Aphekom project by using a two-stage health impact assessment method. We then justify our choice to only consider mortality effects as short-term effects. We rely on European studies when selecting the central value of a life-year estimate (€<sub>2005</sub> 86 600) used to compute the monetary benefits for each of the cities. We also conduct an independent sensitivity analysis as well as an integrated uncertainty analysis that simultaneously accounts for uncertainties concerning epidemiology and economic valuation. **Results:** The implementation of these regulations is estimated to have postponed 2212 (95% confidence interval: 772–3663) deaths per year attributable to reductions in sulphur dioxide for the 20 European cities, from the year 2000 onwards. We obtained annual mortality benefits related to the implementation of the European regulation on sulphur dioxide of €<sub>2005</sub> 191.6 million (95% confidence interval: €<sub>2005</sub> 66.9–€<sub>2005</sub> 317.2). **Conclusion:** Our approach is conservative in restricting to mortality effects and to short-term benefits only, thus only providing the lower-bound estimate. Our findings underline the health and monetary benefits to be obtained from implementing effective European policies on air pollution and ensuring compliance with them over time.

## Introduction

Since the 1970s, air quality has been one of the European Union's major areas of activity. Legislation has led to progress in tackling several air pollutants, including sulphur dioxide (SO<sub>2</sub>), lead, nitrogen oxide, carbon monoxide and benzene.<sup>1</sup> However, other pollutants such as ozone and particulate matter (PM) still require attention.

Reductions in air pollutant levels have long been acknowledged to lead to health benefits including reductions in the number of medical consultations and hospital admissions for respiratory and cardiovascular diseases, and of premature deaths.<sup>2,3</sup> Therefore, assessing the effectiveness of past regulations in terms of both health impacts and avoided health care costs should provide useful input to future regulations. Intervention studies constitute a relevant way to check and help validate results obtained in non-intervention studies, by focusing on the cause–effect relationship involved. In addition, they limit the confounding of issues with respect to other study designs by providing an exogenous change in exposure.<sup>4,5</sup>

A recent review of air pollution interventions reported consistent evidence that improved air quality following an intervention resulted in public health improvements.<sup>6</sup> Almost all intervention studies assessing changes in SO<sub>2</sub> and changes in health outcomes (such as a US nationwide copper smelter strike in the 1960s,<sup>7</sup> the 1990 Irish coal ban,<sup>8</sup> a 1990 regulation restricting the sulphur content of fuel in

Hong Kong<sup>9</sup> or control regulations during the 2008 Beijing Summer Olympic Games<sup>10</sup>) demonstrate beneficial health effects from reducing SO<sub>2</sub> emissions in terms of mortality, asthma visits and cardio-respiratory hospital admissions.

Once the health benefits of an intervention study are estimated, the economic benefits can be assessed and used in cost–benefit analyses. Li *et al.*,<sup>11</sup> for instance, quantified the health benefits of curbing air pollution in Shanghai for two strategies aiming at lowering PM<sub>10</sub> and compared them with the investment costs. They showed that the benefit-to-cost ratios exceed one in both cases (1–5 for the power-sector strategy and 2–15 for the industrial-sector strategy). Chestnut and Mills<sup>12</sup> reconsidered the US Acid Rain Program (Title IV of the 1990 Clean Air Act Amendments) costs and benefits, providing updated estimates of the health benefits. Controlling SO<sub>2</sub> and nitrogen oxide emissions led to total health and environmental benefits of more than US\$100 billion annually in 2010, whereas costs were estimated at US\$3 billion annually.

This paper focuses on the quantification of the monetary benefits resulting from reductions in mortality following the implementation of the European regulation to reduce the sulphur content in liquid fuels. Indeed, European Council (EC) Directive 75/116/EEC limited the sulphur compound content in gas oil to 0.3% by weight (and 0.5% in zones where SO<sub>2</sub> was sufficiently low or insignificantly coming from gas oil) as of 1 October 1980.<sup>13</sup> Then, EC Directive 93/12/EEC introduced a regulation for the SO<sub>2</sub> content permitted in

certain gas oils and diesel fuels, excluding member states seeking derogation<sup>14</sup>: 0.2% by weight as of 1 October 1994 and 0.05% by weight as of 1 October 1996. The maximum sulphur content of certain gas oil fuels for vehicles was further reduced by EC Directive 98/70/EC to 0.035% for diesel fuels and 0.015% for petrol as of 1 January 2000.<sup>15</sup> Council Directive 99/32/EC extended the 93/12/EEC Directive to cover certain liquid fuels derived from petroleum and used by seagoing ships<sup>16</sup> and specifies the following as the permitted maximum SO<sub>2</sub> content: 0.2% by mass as of 1 July 2000 and 0.1% by mass as of 1 January 2008.

Our study used data from 20 cities included in the Aphekom (Improving Knowledge and Communication for Decision Making on Air Pollution and Health in Europe) project, a research programme involving 60 scientists from 12 countries across Europe. Aphekom's objective was to provide new information and tools to enable decision-makers to set more effective European, national and local policies. To this end, it used traditional health impact assessment (HIA) techniques as well as innovative methods to explore the impact of air pollution on health in 25 European cities totalling nearly 39 million inhabitants.

## Methods

### Background

Because the implementation dates for the EC directives on SO<sub>2</sub> were 1994 (first stage), 1996 (second stage) and 2000 (third stage), city-specific daily data on urban background (UB) SO<sub>2</sub> concentrations, temperature and humidity measures and numbers of deaths [all-cause excluding external causes (ICD9: <800)] from 1990 to 2008 were collected using common guidelines based on the Apheis project.<sup>17</sup> Five cities were excluded due to missing data, leaving 20 cities from 11 countries in the analysis (see list in table 1).

However, not all countries complied with the implementation dates as specified in the council directives, because of local derogations for instance. Hence, the number of stages implemented and their corresponding implementation dates were not the same for every city. The following 14 cities implemented all three stages of the council directives: Athens, Bordeaux, Brussels, Dublin, Le Havre,

Lille, London, Lyon, Marseille, Paris, Rome, Rouen, Stockholm and Strasbourg. The other six cities (Barcelona, Bilbao, Budapest, Ljubljana, Toulouse and Vienna) only applied the last implementation stage, namely, Council Directive 99/32/EC. Our analysis assesses the number of deaths from year 2000 onwards (after third implementation stage) compared with the pre-1993 period in all 20 cities. The impacts of each of the three implementation stages on respiratory (ICD9: 460–519), cardiovascular (ICD9: 390–459) and total (ICD9: [I]800) mortality across the 20 cities have been reported in another study.<sup>4</sup>

### Computation of attributable premature deaths

We used a two-stage hierarchical modelling approach to assess the mortality impact of the regulation up to implementation of the third stage. In the first stage, data of each city were analysed separately, whereas in the second stage, evidence across cities was combined using meta-regression techniques. Briefly, for the first stage, city-specific estimates were estimated from a Poisson regression model linking mortality to UB SO<sub>2</sub>, adjusting for temperature, day of the week, seasonality and time trend. Generalized additive models<sup>18</sup> were used to control potential non-linearity between confounders and mortality. The exposure variable used for UB SO<sub>2</sub> was the average of lags 1 and 2 (i.e. 1 and 2 days prior to the mortality event).<sup>4</sup> Additionally, dummy variables and their interaction with UB SO<sub>2</sub> were included in the model, depending on when council directives were successfully implemented in each city. The second stage of the modelling approach was designed to pool the city-specific estimates of air pollution effects on health, using meta-regression techniques.

SO<sub>2</sub> effects on mortality in each city were combined in a meta-analysis based on generalized least squares to provide overall estimates. Variables representing potential effect modifiers (yearly means of SO<sub>2</sub>, PM<sub>10</sub> and temperature) were included in the second-step regression models to account for city heterogeneity. Details on the whole methodology have been previously published,<sup>19</sup> and models were run using R statistical software.<sup>20</sup>

The combined estimate of SO<sub>2</sub> effect on mortality was then used in the HIA to estimate the attributable number of premature deaths (table 1).

### Monetary assessment

#### Special features of the monetary assessment

By reducing UB SO<sub>2</sub> levels in the 20 cities, the regulation has two potential effects on mortality: short-term and long-term.

For acute (or short-term, ST) mortality effects, the number of premature deaths avoided is generally computed through time-series analyses and proportional hazard models. The gains in life expectancy corresponding to each of these premature deaths can be considered to be in the range of a few months, certainly lower than 1 year.<sup>21</sup>

For chronic (or long-term, LT) mortality effects, the number of premature deaths avoided is generally obtained via cohort studies that monitor populations exposed to different levels of pollution. One of the crucial issues is the magnitude of the gain in life expectancy related to these premature deaths. Although no definitive answer exists, a 10-year gain seems to be supported by three types of evidence: medical, epidemiological and empirical from past practice.<sup>21–24</sup>

Depending on whether the mortality effects are acute or chronic, there are two possible ways to deal with the time that elapses between a reduction in air pollution exposure due to the implementation of a regulation and the achievement of full health benefits.

In the 'steady-state' approach, the mortality effects corresponding to two different levels of air pollution are assessed and the number of premature deaths attributed to a change in air pollution exposure is computed as the difference between the numbers of premature

**Table 1** UB SO<sub>2</sub> mean and standard deviation (SD) concentration and number of attributable premature deaths for the 20 EU cities (upper and lower 95% CI bounds)

City	UB SO <sub>2</sub> [µg m <sup>-3</sup> ]		Attributable premature deaths		
	Mean SO <sub>2</sub>	SD of SO <sub>2</sub>	Number of cases	95 CI–	95 CI+
Athens (Greece)	38.97	26.96	507	177	842
Barcelona (Spain)	5.23	5.94	35	12	58
Bilbao (Spain)	17.46	7.19	14	5	24
Bordeaux (France)	7.22	5.06	18	6	29
Brussels (Belgium)	10.04	8.73	54	19	90
Budapest (Hungary)	29.07	19.56	390	136	647
Dublin (Ireland)	19.56	11.07	37	13	61
Le Havre (France)	23.38	28.26	23	8	38
Lille (France)	13.86	14.78	96	34	159
Ljubljana (Slovenia)	8.19	6.32	31	11	52
London (UK)	18.72	23.71	240	84	396
Lyon (France)	11.63	14.75	62	22	103
Marseille (France)	13.48	9.08	66	23	108
Paris (France)	12.16	10.88	314	110	519
Rome (Italy)	9.76	7.81	115	40	191
Rouen (France)	17.21	15.76	46	16	76
Stockholm (Sweden)	4.31	3.28	20	7	33
Strasbourg (France)	11.48	9.56	19	7	31
Toulouse (France)	21.67	15.85	35	12	58
Vienna (Austria)	8.92	11.70	90	31	148
Total	–	–	2212	772	3663

deaths resulting from the respective steady states. This clear, simple and informative approach is accurate for acute (or ST) mortality effects, and provides an idea of the magnitude of the public health problem for chronic (or LT) health effects.

In the 'marginal (benefit)' approach, the impact of a reduction in today's air pollution exposure on the future flow of mortality effects is estimated. Reducing air pollution exposure via the implementation of a regulation in a given year does not produce all its chronic (or LT) effects in the same year because these effects are cumulative.<sup>25–28</sup> This approach is appropriate for cost–benefit analysis where chronic mortality effects are involved: the flow of discounted future benefits can be properly compared with the costs of the policy that generates these benefits.

Although the two approaches are similar for acute (ST) mortality effects, they differ for chronic (LT) mortality effects due to the latency period before the achievement of full mortality benefits and the additional impact of discounting future monetary benefits. In this paper, we consider mortality effects as ST effects only because the health data analysis relies on time-series studies and not on cohort studies. Because it takes a conservative standpoint, the economic evaluation thus constitutes a lower bound of the mortality effects of the regulation.

### Economic values chosen

The valuation of mortality effects follows the standard valuation procedure adopted in Externe,<sup>29</sup> New-Ext<sup>30</sup> or CAFE,<sup>31</sup> which consists in using monetary values derived from stated preferences' surveys, hence relying on preference-derived rather than market-derived values. However, the choice of a proper economic value is crucial because the gain in life expectancy related to a prevented premature death differs according to whether it concerns those affected by chronic or by acute effects (see previous text). Given that we consider ST effects only, the gain in life expectancy associated with each of the premature deaths is assumed to be 'around 1 year',<sup>21</sup> so a value of a life year (VOLY) was chosen here instead of a value of a statistical life.

Because the regulation effects are assessed in European cities, we relied on European studies when selecting the VOLY. To allow for the uncertainty pertaining in the economic valuation, we use a low, a central and a high estimate of a VOLY. First, for the low estimate, we take the recent results from the New Energy Externalities Developments for Sustainability (NEEDS) program<sup>31</sup> (based on a 3-month life expectancy gain with protesters and outliers deleted) conducted in 10 European countries: €<sub>2005</sub> 40 000. Then, for the high estimate, we choose €<sub>2005</sub> 133 200, the mean VOLY (annual change 5:10 000 scenario) obtained in a study representative of the European population, undertaken for the EC DG Research-funded New-Ext<sup>30</sup> project and used in CAFE cost–benefit analysis.<sup>21</sup> Finally, the arithmetic mean of high and low values provides the central VOLY estimate: €<sub>2005</sub> 86 600.

Note that in the absence of reliable country-specific VOLY, the valuation of mortality uses one common VOLY for all cities, because we consider it to be ethically unacceptable to account for differences across countries by ex-post wealth adjustments. Adjusting by gross domestic product per capita, for instance, would lead to a fourfold lower VOLY in Budapest than in Dublin.<sup>32</sup>

## Results

### Results on SO<sub>2</sub> trends

Figure 1 shows a plot of yearly UB SO<sub>2</sub> averages for 12 Aphekom cities from 1990 to 2004 (see Henschel *et al.*<sup>33</sup> for a detailed analysis of the hourly SO<sub>2</sub> pollution patterns for six of the cities). There is no clear step change in UB SO<sub>2</sub> concentrations after implementation of the directives; rather, a gradual decline in SO<sub>2</sub> levels is observed. The decreasing levels over time are probably driven by the successful

implementation of various national and international regulations, including the protocols under the Convention on Long-range Transboundary Air Pollution,<sup>34</sup> the installation of flue gas desulphurization units at power plants and political and economic reforms in Eastern European countries, as well as reductions in the sulphur content in fuel oil.<sup>35</sup> The increase in SO<sub>2</sub> levels in Athens in 2002 and 2003 is mainly related to unfavourable winter conditions but not to structural changes in the sources of emissions. Moreover, rational behaviour in anticipation of an increase in the cost of a tonne of SO<sub>2</sub> (due to desulphurization) may have led some major users of sulphurized fuel before 1994 to switch to natural gas prior to the implementation of the regulation.

### Results on HIA

Inference by eye<sup>36</sup> did not provide evidence of changes in the slope of the SO<sub>2</sub>–mortality dose–response curve after implementation of the different legislations: 0.62 (95% CI: 0.3–0.95) before 1994, 0.71 (95% CI: 0.01–1.4) between 1994 and 1996, 0.64 (95% CI: 0.09–1.19) between 1996 and 2000 and 1.16 (95% CI: –0.67 to 3.02) after 2000. This is not altogether unexpected because it is consistent with a linear dose–response curve down to very low concentrations. Over the study period, a decrease of 10 µgm<sup>–3</sup> in UB SO<sub>2</sub> levels was associated with a (pooled) decrease in daily all-cause mortality of 0.53% (95% CI: 0.18–0.83). These findings were broadly comparable with results from the APHEA multi-city study in Europe: Katsouyanni *et al.*<sup>37</sup> found that an increase of 50 µgm<sup>–3</sup> in SO<sub>2</sub> was associated with an approximate increase of 3% for all-cause mortality.

Applying the two-stage approach to city-specific mortality incidence and SO<sub>2</sub> level increases from pre- to post-intervention period, the HIA analysis of the mortality data suggests an overall 2212 (95% CI: 772–3663) premature deaths avoided per year associated with decreases in SO<sub>2</sub> for 20 cities from year 2000 onwards (after third implementation stage) compared with the pre-1993 period (see column labelled 'Attributable premature deaths' in table 1 for results by city with the corresponding 95% CI). The lowest number of postponed deaths attributable to the regulation is obtained in Bilbao (14) and the highest in Athens (507).

### Mortality benefits


#### Results and sensitivity analysis

Based on the number of premature deaths computed in table 1 and the central estimate associated with a premature death avoided (€86 600), the annual economic benefit related to the implementation of the EC regulations on SO<sub>2</sub> amounts to €191.6 million (95% CI: €66.9 million–€317.2 million). The detailed results as well as the upper and lower 95% CI bounds for each city are given in table 2. Bilbao obtains the lowest annual economic benefits, with €1.2 million (95% CI: €0.4 million–€2.1 million), and Athens obtains the highest, with €43.9 million (95% CI: €15.3 million–€72.9 million).

We perform a sensitivity analysis specific to the economic valuation by applying the low (€40 000) and high (€133 200) estimates of the VOLY to the number of premature deaths provided by the epidemiological computations. Results are presented in table 2 and represent a range of monetary benefits (low and high) for the number of premature deaths as well as for the related upper and lower 95% CI bounds.

### Uncertainty analysis

Uncertainty analysis simultaneously accounts for uncertainties concerning epidemiology and economic valuation through an integrated approach. The results of the HIA and the economic values are treated as random variables with specified distributions of probability. Monte Carlo simulations are used to propagate the



**Figure 1** Plot of yearly UB SO<sub>2</sub> averages of 12 Aphekcom cities\* from 1990 to 2004 (\*of the nine French cities involved in the project, only Paris is included here)

**Table 2** Annual monetary benefits for the 20 EU from 2000 onwards compared with the pre-1993 period (central, low and high estimates of the number of premature deaths and of the upper and lower 95% CI bounds)


City	Monetary valuation (million € 2005)								
	Central estimate (VOLY = €86 600)			Low estimate (VOLY = €40 000)			High estimate (VOLY = €133 200)		
	Benefits	95 CI-	95 CI+	Benefits	95 CI-	95 CI+	Benefits	95 CI-	95 CI+
Athens	43.9	15.3	72.9	20.3	7.1	33.7	67.5	23.6	112.2
Barcelona	3.0	1.0	5.0	1.4	0.5	2.3	4.7	1.6	7.7
Bilbao	1.2	0.4	2.1	0.6	0.2	1.0	1.9	0.7	3.2
Bordeaux	1.6	0.5	2.5	0.7	0.2	1.2	2.4	0.8	3.9
Brussels	4.7	1.6	7.8	2.2	0.8	3.6	7.2	2.5	12.0
Budapest	33.8	11.8	56.0	15.6	5.4	25.9	51.9	18.1	86.2
Dublin	3.2	1.1	5.3	1.5	0.5	2.4	4.9	1.7	8.1
Le Havre	2.0	0.7	3.3	0.9	0.3	1.5	3.1	1.1	5.1
Lille	8.3	2.9	13.8	3.8	1.4	6.4	12.8	4.5	21.2
Ljubljana	2.7	1.0	4.5	1.2	0.4	2.1	4.1	1.5	6.9
London	20.8	7.3	34.3	9.6	3.4	15.8	32.0	11.2	52.7
Lyon	5.4	1.9	8.9	2.5	0.9	4.1	8.3	2.9	13.7
Marseille	5.7	2.0	9.4	2.6	0.9	4.3	8.8	3.1	14.4
Paris	27.2	9.5	44.9	12.6	4.4	20.8	41.8	14.7	69.1
Rome	10.0	3.5	16.5	4.6	1.6	7.6	15.3	5.3	25.4
Rouen	4.0	1.4	6.6	1.8	0.6	3.0	6.1	2.1	10.1
Stockholm	1.7	0.6	2.9	0.8	0.3	1.3	2.7	0.9	4.4
Strasbourg	1.6	0.6	2.7	0.8	0.3	1.2	2.5	0.9	4.1
Toulouse	3.0	1.0	5.0	1.4	0.5	2.3	4.7	1.6	7.7
Vienna	7.8	2.7	12.8	3.6	1.2	5.9	12.0	4.1	19.7
Total	191.6	66.9	317.2	88.5	30.9	146.5	294.6	102.8	487.9

uncertainty in the numbers of premature deaths and the VOLY, by drawing random samples from the distributions. Each draw generates an estimate of the annual monetary benefits, and a sufficient number of draws makes it possible to characterize the distribution of these monetary benefits.<sup>38</sup>

A normal distribution is used to characterize the spread of the mortality data, defined in terms of its mean and standard deviation.

This choice relies on the assumptions and data obtained by the HIA. A triangular distribution is used for the VOLY, defined in terms of a modal central value, a maximum and a minimum. The triangular distribution is typically used when knowledge of the variable is more subjective than objective.

Once these probability distributions are defined, the model is run using 10 000 Monte Carlo samples and provides probabilized



**Figure 2** Probability distribution of the annual monetary benefits for the 20 EU cities (generated from Monte Carlo sampling over 10 000 iterations)

distributions of the product of the annual number of postponed deaths and the VOLY, representing the annual mortality benefits. Figure 2 shows the distribution of the annual mortality benefits for the 20 EU cities that implemented the third implementation stage. The mean is €191.44 million, and the empirical 95% CI is €57.5 million–€363.6 million. This range is slightly wider than the range obtained previously because it accounts jointly for epidemiological and economic uncertainties.

## Discussion

Our findings underline the health and monetary benefits obtained from drafting and implementing effective EU policies on air pollution, and by ensuring compliance with them over time. They show a marked and sustained reduction in ambient SO<sub>2</sub> levels over time in the 20 cities. Some of this decrease is attributable to the implementation of Council Directive 93/12/EEC and its amended version, and we estimate that some 2200 premature deaths were prevented annually, valued at €192 million.

We should bear in mind that SO<sub>2</sub> emissions have long been acknowledged to also generate direct monetary effects on morbidity<sup>39</sup> and crops,<sup>40,41</sup> as well as more intangible effects on the environment<sup>42,43</sup> that were not assessed in our study. Chestnut and Mills,<sup>12</sup> when assessing the US Acid Rain Program benefits, account for effects on ST and LT human health benefits as well as visibility, natural resources and deposition on materials. This paper thus only partially evaluates the full economic benefits of the regulation, as it limits itself to ST mortality effects.

Moreover, although the regulation on SO<sub>2</sub> has two potential effects on mortality, ST and LT, we take a conservative standpoint, restricting mortality effects to ST effects and consequently valuing them with a VOLY instead of a value of a statistical life. The economic evaluation thus constitutes a lower bound of the mortality gains of the regulation.

Finally, we should acknowledge that the benefits of SO<sub>2</sub> reduction may also have arisen from reductions in other pollutants. SO<sub>2</sub> was not the only pollutant to decrease over the period studied, black smoke, for instance, also decreases, and we cannot distinguish the separate effects of the various pollutants. Thus, care should be taken in future work not to double count by repeating the analysis on

other pollutants and totalling the results. Moreover, the concentration–response functions used to assess the mortality impact are derived from observational studies that only provide evidence for associations, and causality cannot be inferred because other (non-pollution) factors cannot be ruled out.

## Acknowledgements

The huge amount of work behind the Aphekom project is the fruit of generous and constructive input from all the members of the Aphekom network. The Aphekom project was co-funded by the European Commission's Programme on Community Action in the Field of Public Health (2003–8) under Grant Agreement No. 2007105 and by the many national and local institutions that dedicated resources to the fulfilment of this project. We wish to mention our thanks and appreciation of all their contributions. The authors thank J.-P. Lacharme, A. Lefranc, M. Sweetko, J.-M. Thiolet and two anonymous reviewers for helpful suggestions on the manuscript.

## Funding

This work was supported by the European Commission's Programme on Community Action in the Field of Public Health (2003–8) [2007105].

*Conflicts of interest:* None declared.

## Keypoints

- We quantify the monetary benefits resulting from reductions in mortality following the implementation of the European regulation to reduce the sulphur content in liquid fuels.
- We find a marked and sustained reduction in ambient SO<sub>2</sub> levels over time for 20 European cities, and we estimate that some 2200 premature deaths were prevented annually, valued at €192 million.
- We perform both sensitivity and uncertainty analyses and obtain a slightly wider range for the latter, as it jointly accounts for epidemiological and economic uncertainties.

- Our findings underline the health and monetary benefits obtained from drafting and implementing effective EU policies on air pollution, and by ensuring compliance with them over time.
- By assessing the effectiveness of past regulations in terms of both health impacts and avoided health costs, we provide useful input to future regulations.

## References

- European Commission. Air Pollution Policy Review 2011–2013. Available at: [http://ec.europa.eu/environment/air/index\\_en.htm](http://ec.europa.eu/environment/air/index_en.htm) (11 December 2013, date last accessed).
- MacKenzie VG. *Air pollution needs action now*. Washington DC: Department of Health, Education, and Welfare, 1961.
- Hall JV, Winer AM, Kleinman MT, et al. Valuing the health benefits of clean air. *Science* 1992;255:812–17.
- Le Tertre A, Henschel S, Analitis A, et al. Comparing health impacts before and after a strategy to reduce air pollution in Europe - the Aphekom Project. *Air Qual Atm Health* 2014 doi: 10.1007/s11869-013-0215-x.
- Pope CA III. Appendix C. Accountability studies of air pollution and human health: where are we now and where does the research go next? In: Proceedings of an HEI Workshop on Further research to assess the health impacts of actions taken to improve air quality, Communication 15. Boston, MA: Health Effects Institute, 2010. Available at: <http://pubs.healtheffects.org/view.php?id=346> (11 December 2013, date last accessed).
- Henschel S, Atkinson R, Zeka A, et al. A literature review: air pollution interventions and their impact on public health. *Int J Pub Health* 2012;57:757–68.
- Pope CA III, Rodermund DL, Gee MM. Mortality effects of a copper smelter strike and reduced ambient sulfate particulate matter air pollution. *Env Health Persp* 2007;115:679–83.
- Clancy L, Goodman PG, Sinclair H, Dockery DW. Effect of air-pollution control on death rates in Dublin, Ireland: an intervention study. *Lancet* 2002;360:1210–14.
- Hedley AJ, Wong C-M, Thach TQ, et al. Cardiorespiratory and all-cause mortality after restrictions on sulphur content of fuel in Hong Kong: an intervention study. *Lancet* 2002;360:1646–52.
- Li Y, Wang W, Kan H, et al. Air quality and outpatient visits for asthma in adults during the 2008 Summer Olympic Games in Beijing. *Sci Tot Env* 2010;408:1226–7.
- Li J, Guttikunda SK, Carmichael GR, et al. Quantifying the human health benefits of curbing air pollution in Shanghai. *J Env Man* 2004;70:49–62.
- Chestnut LG, Mills DM. A fresh look at the benefits and costs of the US acid rain program. *J Env Manag* 2005;77:252–66.
- Official Journal of the European Communities: Council Directive 75/716/EEC of 24 November 1975 on the approximation of the laws of the Member States relating to the sulphur content of certain liquid fuels. L 307/22 (1975).
- Official Journal of the European Union: Council Directive 93/12/EEC of 23 March 1993 relating to the sulphur content of certain liquid fuels. L 074 (1993).
- Official Journal of the European Communities: Directive 98/70/EC of the European Parliament and of the Council of 13 October 1998 relating to the quality of petrol and diesel fuels and amending Council Directive 93/12/EEC. L 350/58 (1998).
- Official Journal of the European Union: Council Directive 1999/32/EC of 26 April 1999 relating to a reduction in the sulphur content of certain liquid fuels and amending Directive 93/12/EEC.
- Medina S, Boldo E, Saklad M. *Health Impact Assessment of Air Pollution and Communications Strategy (Aphis)*. Saint-Maurice, France: Institut de Veille Sanitaire, third year report, 2005. Available at: <http://www.aphis.org/vfbisnvsAphis.pdf> (11 December 2013, date last accessed).
- Wood SN. Fast stable restricted maximum likelihood and marginal likelihood estimation of semiparametric generalized linear models. *J Roy Stat Soc Ser B (Stat Meth)* 2011;73:3–36.
- Touloumi G, Atkinson R, Le Tertre A, et al. Analysis of health outcome time series data in epidemiological studies. *Environmetrics* 2004;15:101–17.
- R Development Core Team. *A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing, 2011.
- Hurley F, Hunt A, Cowie H, et al. Methodology for the cost-benefit analysis for CAFE. In: *Health Impact Assessment*, Vol. 2, Oxon, UK: AEA Technology Environment, 2005. Available at: [http://ec.europa.eu/environment/archives/cafepdf/cba\\_methodology\\_vol2.pdf](http://ec.europa.eu/environment/archives/cafepdf/cba_methodology_vol2.pdf) (15 February 2014, date last accessed).
- Ezzati M, Lopez A, Rodgers A, et al. Selected major risk factors and global and regional burden of disease. *Lancet* 2002;360:1347–60.
- Watkiss P, Pye S, Holland M. *Baseline Analysis 2000 to 2020 service contract for carrying out cost-benefit analysis of air quality related issues, in particular in the Clean Air for Europe (CAFE)*. Oxon, UK: AEA Technology Environment, 2005, Programme AEAT/ED51014/Baseline Scenarios, Issue 5.
- Janke K, Propper C, Henderson J. Do current levels of air pollution kill? The impact of air pollution on population mortality in England. *Health Econ* 2009;18:1031–55.
- Leksell I, Rabl A. Air pollution and mortality: quantification and valuation of years of life lost. *Risk Anal* 2001;21:843–57.
- Miller B, Hurley F. Life table methods for quantitative impact assessments in chronic mortality. *J Epi Com Health* 2003;57:200–6.
- Röösli M, Künzli N, Braun-Fahrlander C, Egger M. Years of life lost attributable to air pollution in Switzerland: dynamic exposure-response model. *Int J Epid* 2005;34:1029–35.
- Chanel O, Scapecchi P, Vergnaud J-C. How to correctly assess mortality benefits in public policies. *J Env Plan Manag* 2006;49:759–76.
- Holland MR, Forster D. *DGXII (JOULE Programme) Externalities of Energy*. Bruxelles, Belgium: ExternE Project, 1999. Report Number 7, Methodology: Update 1998.
- Institute for Energy Economics and the Rational Use of Energy (IER), et al. *New Elements for the Assessment of External Costs from Energy Technologies (New-Ext)*. Stuttgart, Germany: IER; 2004. Contract No: ENGI-CT2000–00129.
- Desaigues B, Ami D, Bartzczak A, et al. Economic valuation of air pollution mortality: a 9-country contingent valuation survey of Value of a Life Year (VOLY). *Ecol Indic* 2011;11:902–10.
- World Bank. World Development Indicators database, 2010. Available at: <http://databank.worldbank.org/> (11 December 2013, date last accessed).
- Henschel S, Querol X, Atkinson RW. Ambient air SO<sub>2</sub> patterns in 6 European cities. *Atm Env* 2013;79:236–47.
- World Health Organization. *Air quality guidelines for particulate matter, ozone, nitrogen dioxide and sulphur dioxide—Global update 2005*. Copenhagen, Denmark: WHO Regional Office for Europe, 2006. Available at: [http://www.euro.who.int/\\_data/assets/pdf\\_file/0005/78638/E90038.pdf](http://www.euro.who.int/_data/assets/pdf_file/0005/78638/E90038.pdf) (11 December 2013, date last accessed).
- Lövlad V, Tarrasón L, Tørseth K, Dutchak S. European Monitoring and Evaluation Programme (EMEP). In: *Assessment Part I European Perspective*. Norway: Norwegian Meteorological Institute, 2004: Chapter 2, 35: 15–46.
- Cumming G. Inference by eye: reading the overlap of independent confidence intervals. *Stat Med* 2009;28:205–20.
- Katsouyanni K, Touloumi G, Spix C, et al. Short-term effects of ambient sulphur dioxide and particulate matter on mortality in 12 European cities: results from time series data from the APHEA project. *Brit Med J* 1997;314:1658–63.
- Burmaster DE, Anderson PD. Principles of good practice for the use of Monte Carlo techniques in human health and ecological risk assessment. *Risk Anal* 1994;14:477–81.
- Cropper ML. Measuring the benefits from reduced morbidity. *Am Econ Rev* 1981;71:235–40.
- Eyres NJ, Ozdemiroglu E, Pearce DW, Steele P. Fuel and location effects on the damage costs of transport emissions. *J Transp Econ Pol* 1997;31:5–24.
- Environmental Protection Agency. *The benefits and costs of the clean air act, 1970 to 1990*. Washington DC: US-Environmental Protection Agency; 1999. Report to Congress Environmental Protection Office of Policy No.: EPA-410-R-99-001.
- Randall A, Yves B, Eastman C. Bidding games for valuation of aesthetic environmental improvements. *J Env Econ Man* 1974;1:132–49.
- Gregory K, Webster C, Durk S. Estimates of damage to forests in Europe due to emissions of acidifying pollutants. *Energy Pol* 1996;24:655–64.